Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

The Economic Burden of Moderate-to-Severe Ulcerative Colitis in the EU5

Speaker(s)

Cichewicz A1, Tencer T2, Egodage S1, Burnett H1, Kumar J3
1Evidera, Waltham, MA, USA, 2Bristol Myers Squibb, Princeton, NJ, USA, 3Bristol Myers Squibb, San Diego, CA, USA

Presentation Documents

Objective: This systematic literature review aimed to quantify the economic burden of moderate-to-severe ulcerative colitis (UC) in the European Union Five (EU5) and identify key drivers.

Methods: Systematic searches were conducted in October 2021 in MEDLINE, Embase, the Database of Abstracts of Reviews of Effects, and the National Health Service Economic Evaluation Database. Real-world studies published since 2010 reporting direct healthcare and indirect work-related costs and healthcare resource use (HCRU) among adults with moderate-to-severe UC in the EU5 were included. Two independent reviewers screened 2,206 unique records. Costs were converted to 2019 Euros.

Results: A total of 25 unique studies (31 publications) were included: 6 reported healthcare costs only, 8 reported HCRU only, and 11 reported costs and HCRU. Patient characteristics, interventions, study settings, and study years varied across studies.

Overall direct healthcare costs varied by treatment type and disease severity and were largely driven by prescription drug costs. Patients on advanced therapies such as anti-tumor necrosis factor agents, vedolizumab, or tofacitinib had higher direct costs (€24,552 - €34,068 per patient year [PPY] on stable dose vs. €39,514/PPY on escalated dose) than patients on non-biological treatments such as corticosteroids and/or immunosuppressants (€4,708 PPY for non-active disease vs. €8,655 PPY for active disease).

Moderate-to-severe UC patients with active disease reported significantly higher rates of absenteeism, presenteeism and overall work impairment (29.3% vs. 3.7%, p<0.05; 49.09% vs. 16.02%, p<0.05; and 54.35% vs. 19.38%, p<0.05) compared to those in remission. Introduction of advanced treatments is associated with a considerable reduction in both direct and indirect costs.

Conclusion: Moderate-to-severe UC has a significant impact on direct healthcare costs (outpatient, hospitalization, and prescription) and indirect work-related costs (absenteeism, presenteeism, and work productivity) in the EU5. There remains an unmet need for additional therapies that can further reduce the healthcare burden and impact on society.

Code

EE312

Topic

Economic Evaluation

Disease

Gastrointestinal Disorders